Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM)

Authors :: Alberto Muzio
Andreas Polychronis
Mary O'Brien
Ryaz Shah
Paul D. Taylor
Alessandra Bearz
Pawel Badurak
Vanesa Gregorc
Paolo Bidoli
Silvia Novello
Francesco Grossi
Claudio Bordignon
Marcello Tiseo
Adolfo Favaretto
Antonio Lambiase
Jacek Jassem
Rabab Gaafar
Laurent Greillier
Source :: ResearcherID
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: 7501 Background: Currently, there are no standard options for MPM patients who failed a pemetrexed-based chemotherapy (CT). NGR-hTNF, a tumor-targeted antivascular agent, displays antitumor activit...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
Pleural mesothelioma
business.industry
medicine.medical_treatment
Placebo
Surgery
Pemetrexed
NGR-hTNF
Internal medicine
medicine
Previously treated
business
medicine.drug

Tools